Clinical Trials

Phase IV trial investigating the safety, efficacy and durability of Faricimab administered up to 24 weeks in the treatment of Wet Age-Related Macular Degeneration.

• Inclusion: 50yrs +, VA between 6/7.5 and 6/75, treatment naïve
• Exclusion: History of macular pathology unrelated to AMD. Cataract surgery of YAG within the last 3 months. History of stroke within the last 6 months.

A phase 3 study evaluating the efficacy and safety of Intravitreal OTX-TKI (Axitinib Implant) in the treatment of Neovascular Age-Related Macular Degeneration.

• Inclusion: 50yrs +, VA better than 6/60, CST <350um, treatment naïve or previously treated with up to 3 previous injections
• Exclusion: Uncontrolled glaucoma. Cataract surgery, laser or ocular infection within the last 3 months. Previous treatment with pegcetacoplin.

A Phase 3 study investigating the efficacy and safety of intravitreal injections of ANX007 for Geographic Atrophy.

• Inclusion: 50yrs +, VA between 6/7.5 - 6/30, GA lesions 2.5-17mm^2
• Exclusion: Uncontrolled glaucoma or surgery for glaucoma, previous IVT injections in designated study eye, cataract surgery <3 months ago

A Phase 2/3 study evaluating the efficacy and safety of EYE103 compared to Ranibizumab in treatment of Diabetic Macular Edema.

• Inclusion: 18yrs old+, treatment naïve or previously treated AMD <3years from diagnosis, VA 6/9.5-6/95, CST >325um, Hba1c <12%
• Exclusion: Renal failure. Active PDR. Recent stroke / heart attack / cataract or glaucoma surgery. Previous vitrectomy, glaucoma filtering surgery, uveitis or retinal detachment. Presence of ocular inflammation / ERM / pathological myopia / amblyopia.

A Phase III study evaluating the safety and efficacy of Faricimab in myopic CNV.

• Inclusion: 18yrs old+, Treatment naive myopic CNV, VA 6/12-6/95, AXL >26.0mm, Myopia -6D or worse
• Exclusion: Previous intravitreal injections, laser, vitrectomy, glaucoma surgery, corneal transplant. Presence of ocular inflammation, CSR, schisis, ERM, previous retinal tear

A Phase III study of KHK4951 eyedrops to explore safety and efficacy in the treatment of diabetic macula oedema.

• Inclusion: 18yrs+, treatment naïve or previously treated DMO <3 years from diagnosis, VA 6/9.5-6/60, CST 325um-500um, HbA1c <11%, BP <140/90.
• Exclusion: AntiVEGF within 12 weeks, History of stroke / TIA / blood clots / bleeding disorders. Proliferative diabetic retinopathy. Previous macular laser, PDT laser, glaucoma surgery, corneal transplant.

A Phase II study of KHK4951 eye drops to explore safety and efficacy in the treatment of wet age related macular degeneration.

• Inclusion: 50yrs old+, treatment naive or previously treated AMD <3years from diagnosis with active leakage at the fovea. VA 6/9.5-6/60, CST <450um, BP under 150/100
• Exclusion: AntiVEGF within 12 weeks, History of stroke / TIA / blood clots / bleeding disorders. Previous macular laser, PDT laser, glaucoma surgery, corneal transplant. Subretinal hemorrhage / fibrosis / atrophy that involves the fovea.

A phase III study of Tinlarebant to explore safety and efficacy in the treatment of geographic atrophy (GA).

• Inclusion: 60-85 yrs old, VA 6/24 or better, GA lesion 1-10mm^2 (foveal involvement <1.25mm^2 in either eye) BMI <40, HBa1c <8%
• Exclusion: Presence of DMO, macular disease or other retinal vascular conditions, Medications containing Vitamin A or Retinoids that can’t be stopped.

A phase IIb study of intravitreal gene therapy treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

• Inclusion: 60yrs old+, GA lesion 2.5-17.5mm^2 (non subfoveal), VA 6/45 or better
• Exclusion: Previous CNV, presence of diabetic retinopathy, CSR, retinal vascular disease, macular hole, macular fibrosis. Previous macular laser, PDT laser, vitrectomy, glaucoma surgery, corneal transplant.

Treat & Extend versus Fixed dosing with Faricimab for management of Diabetic Macular Oedema (DMO).

• Inclusion: Foveal involving DMO, CST >325um, VA 6/7.5-6/120. Hba1c <10%
• Exclusion: Previous macular laser, antiVEGF within 12 weeks, DMO persisting for more than 2 years.

Assessing the efficacy and durability of intravitreal Faricimab in patients currently treated for neovascular age-related macular degeneration (nAMD).

• Inclusion: CNV diagnosed <3 years ago, most recent treatment within last 3 months, active CNV affecting central subfield, VA 6/120 or better
• Exclusion: Presence of geographic atrophy / fibrosis, vitreous hemorrhage.

A phase III study of the efficacy and safety of Aflibercept 8 mg in Macular Oedema secondary to Retinal Vein Occlusion.

A phase III, multicentre, double-masked, randomised study to evaluate the efficacy and safety of Intravitreal OPT-302 in combination with Aflibercept, compared with Aflibercept alone, in participants with neovascular age-related macular degeneration (nAMD).

A phase III, open-label, multicenter, Oaks extension study to evaluate the long-term safety and efficacy of Pegcetacoplan in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

A phase II, double-masked, placebo-controlled, dose range finding study of Danicopan in patients with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD).

A long-term extension study for Participants enrolled in Parasol.